Prognostic significance of p53 mutation in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin

Neijt, 1996, New therapy for ovarian cancer, N. Engl. J. Med., 334, 50, 10.1056/NEJM199601043340112 Demers, 1994, Growth arrest by induction of p53 in DNA damaged keratinocytes is bypassed by human papillomavirus 16 E7, Proc. Natl Acad. Sci. USA, 91, 4382, 10.1073/pnas.91.10.4382 Harris, 1996, Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies, J. Natl Cancer Inst., 88, 1442, 10.1093/jnci/88.20.1442 Vasey, 1996, Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance, Mol. Pharmacol., 50, 1536 Harris, 1993, Clinical implications of the p53 tumor-suppressor gene, N. Engl. J. Med., 329, 1318, 10.1056/NEJM199310283291807 Buttitta, 1997, p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study, Br. J. Cancer, 75, 230, 10.1038/bjc.1997.38 Havrilesky, 2003, Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a gynecologic oncology group study, J. Clin. oncol., 21, 3814, 10.1200/JCO.2003.11.052 Lavarino, 2000, p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma, J. Clin. oncol., 18, 3936, 10.1200/JCO.2000.18.23.3936 Claij, 1999, Microsatellite instability in human cancer: a prognostic marker for chemotherapy?, Exp. Cell Res., 246, 1, 10.1006/excr.1998.4299 Young, 2003, DNA mismatch repair proteins: potential guardians against genomic instability and tumorigenesis induced by ultraviolet photoproducts, J. Invest. Dermatol., 121, 435, 10.1046/j.1523-1747.2003.12450.x Griffin, 1994, DNA mismatch binding and incision at modified guanine bases by extracts of mammalian cells: implications for tolerance to DNA methylation damage, Biochemistry (Moscow), 33, 4787, 10.1021/bi00182a006 Fink, 1996, The role of DNA mismatch repair in platinum drug resistance, Cancer Res., 56, 4881 Fujita, 2003, Genetic alterations in ovarian carcinoma: with specific reference to histological subtypes, Mol. Cell Endocrinol., 202, 97, 10.1016/S0303-7207(03)00069-8 Mikker, 1981, Reporting results of cancer treatment, Cancer, 41, 207 Kuragaki, 2003, Mutations in the STK11 gene characterize minimal deviation adenocarcinoma of the uterine cervix, Lab. Invest., 83, 35, 10.1097/01.LAB.0000049821.16698.D0 Fujita, 1994, Alteration of the p53 tumor suppressor gene occurs independently of K-ras activation and more frequently in serous adenocarcinomas than in other common epithelial tumors of the human ovary, Jpn. J. Cancer Res., 85, 1247, 10.1111/j.1349-7006.1994.tb02937.x Boland, 1998, A national cancer institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer, Cancer Res., 58, 5248 Ozaki, 2001, Impaired FHIT expression characterizes serous ovarian carcinoma, Br. J. Cancer, 85, 247, 10.1054/bjoc.2001.1886 Reles, 2001, Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer, Clin. Cancer Res., 7, 2984 Rose, 2003, The impact of p53 protein core domain structural alteration on ovarian cancer survival, Clin. Cancer Res., 9, 4139 Fujita, 1995, Microsatellite instability and alternations in the hMSH2 gene in human ovarian cancer, Int. J. Cancer, 64, 361, 10.1002/ijc.2910640602 Righetti, 1996, A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma, Cancer Res., 56, 689